

LITERATURA

1. Horák I, Vohánka S, Tvrđíková E, Horáková M, Bednařík J. Statiny indukované nekrotizující autoimunitní myopatie. *Cesk Slov Neurol N* 2017; 80(113): 549–577.

2. Bednařík J, Vlčková E, Horák T. Statinová myopatie. *Neurol praxi* 2017; 18(1): 9–10.

3. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. *J Am Coll Cardiol*. 2002; 40(3): 567–572.

4. Mohaupt MG, Karas RH, Babychuk EB, et al. Association between statin-associated myopathy and skeletal muscle

damage. *CMAJ*. 2009; 181(1–2): E11–E18.

5. Tournadre A. Statins, myalgia, and rhabdomyolysis. *Joint Bone Spine*. 2020; 87(1): 37–42.

6. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. *Cardiovasc Drugs Ther*. 2005; 19(6): 403–414.

7. Alfirevic A, Neely D, Armitage J, et al. Phenotype standardization for statin-induced myotoxicity. *Clin Pharmacol Ther*. 2014 Oct; 96(4): 470–476.

8. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. *Circulation*. 2013; 127(1): 96–103.

9. Turner RM, Pirmohamed M. Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. *J Clin Med*. 2019; 9(1): 22.

10. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet* 2010; 375: 735–742.

11. Schmidt J. Current Classification and Management of Inflammatory Myopathies. *J Neuromuscul Dis*. 2018; 5(2): 109–129.

12. Allenbach Y, Benveniste O. Diagnostic Utility of Auto-Antibodies in Inflammatory Muscle Diseases. *J Neuromuscul Dis*. 2015; 2(1): 13–25.